..

Lamotrigine-Related Severe Cutaneous Adverse Reaction in Patient with Epilepsy

Abstract

Al-Quliti KW

Background: Epilepsy is a common neurological disorder for which lamotrigine is an effective antiepileptic medication as monotherapy or as an add-on therapy with good tolerability and safety profile. Side effects, including serious skin reactions, can develop during treatment with lamotrigine and can be life threatening. The aim of this research is to study the local experience of adult Saudi patients with epilepsy who developed lamotrigine-related skin reactions.
Methods: This observational retrospective study included all epilepsy patients who received lamotrigine and were followed up in the adult epilepsy clinic at King Fahad Hospital, Madinah, Saudi Arabia, between July 2011 and June 2014.
Results: A total of 147 epilepsy patients received lamotrigine. Eleven patients (7.48%), aged 24 to 62 years old (mean 39.73 SD 11), of which 6 were male (54.5%) and 5 female (45.5%), developed cutaneous adverse drug reactions. Lamotrigine was used as monotherapy in one patient and as add-on therapy for 10 patients. Eight patients (72.73%) had high liver enzymes. Seven patients (63.6%) had systemic symptoms. Cutaneous adverse drug reactions were noted 1 to 4 weeks after lamotrigine initiation (mean=2.36, mode=3); 7 patients (63.63%) had maculopapular rashes, and 4 patients (36.37%) had urticaria. Six patients (54.5%) had good recovery; 1 patient developed sepsis; 2 patients developed hyperpigmentations; and 2 patients developed drug reactions with eosinophilia and systemic symptoms. Conclusion: Lamotrigine is an effective medication for management of epilepsy and other nervous system disorders, with a good tolerability and safety profile. However, lamotrigine-related cutaneous adverse drug reactions can be serious and healthcare providers’ thorough clinical knowledge of the potential side effects of lamotrigine is crucial in clinical practice particularly when patients receive multiple antiepileptic drugs.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证

分享此文章

索引于

相关链接

arrow_upward arrow_upward